The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 23-31

  Ohte, Nobuyuki ^a   Cheng, Che Ping ^a   Suzuki, Makoto ^a   Little, William C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG MECHANISM; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE SIZE; HEART PACING; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE;

AMRINONE; ANIMALS; DOGS; HEART FAILURE, CONGESTIVE; PHOSPHODIESTERASE INHIBITORS; PHYSICAL CONDITIONING, ANIMAL; PYRIDAZINES; VENTRICULAR FUNCTION, LEFT;

EID: 0030759111     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ASANOI, H., ISHIZAKA, S., KAMEYAMA, T. AND SASAYAMA, S.: Neural modulation of ventriculoarterial coupling in conscious dogs. Am. J. Physiol. 266: H741-H748, 1994.
2. BAUMANN, G., NINGEL, K AND PERMANETTER, B.: Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure. J. Cardiovasc. Pharmacol. 14:(suppl 2), S23-30, 1989.
3. BAYLISS, J., NORELL, M., CANEPA-ANSON, R., REUBEN, S. R., POOLE-WILSON, P. A. AND SUTTON, G. C.: Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. Br. Heart J. 49: 214-221, 1983.
4. BERGER, C., MEYER, W., SCHOLZ, H. AND STARBATTY, J.: Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) benzimidazole-HC1 on phosphodiesterase activity and force of contraction in guinea-pig hearts. Arzneim.-Forsch./Drug Res. 35: 1668-1673, 1985.
5. BOHM, M., BEUCKELMANN, D., BROWN, L., FEILER, G., LORENZ, B., NABAUER, M., KEMKES, B. AND ERDMANN, E.: Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur. Heart J. 9: 844-852, 1988a.
6. BOHM, M., DIET, F., FEILER, G., KEMKES, B., KREUZER, E., WEINHOLD, C. AND ERDMANN, E.: Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J. Cardiovasc. Pharmacol. 12: 726-732, 1988b.
7. BOHM, M., GIERSCHIK, P., JAKOBS, K. H., PIESKE, B., SCHNABEL, P., UNGERER, M. AND ERDMANN, E.: Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249-1265, 1990.
8. BOHM, M., MORANO, I., PIESKE, B., RUEGG, J. C., WANKERL, M., ZIMMERMANN, R. AND ERDMANN, E.: Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ. Res. 68:689-701, 1991.
9. BRISTOW, M. R., GINSBURG, R., UMANS, V., FOWLER, M., MINOBE, W., RASMUSSEN, R., ZERA, P., MENLOVE, R., SHAH, P., JAMIESON, S. AND ET AL.: Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ. Res. 59: 297-309, 1986.
10. BRUNKHORST, D., V.DER LEYEN, H., MEYER, W., NIGBUR, R., SCHMIDT-SCHUMACHER, C. AND SCHOLZ, H.: Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 339: 575-583, 1989.
11. CHENG, C. P., IGARASHI, Y. AND LITTLE, W. C.: Mechanism of augmented rate of left ventricular filling during exercise. Circ. Res. 70: 9-19, 1992.
12. CHENG, C. P., NODA, T., NOZAWA, T. AND LITTLE, W. C.: Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ. Res. 72: 795-806, 1993.
13. CHIDSEY, C. S., HARRISON, D. C. AND BRAUNWALD, E.: Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N. Engl. J. Med. 267: 650-654, 1962.
14. DUNCKER, D. J., HARTOG, J. M., LEVINSKY, L. AND VERDOUW, P. D.: Systemic haemodynamic actions of pimobendan (UD-CG 115 BS and its O-demethylmetabolite UD-CG 212 C1 in the conscious pig. Br. J. Pharmacol. 91: 609-615, 1987.
15. ENDOH, M., SHIBASAKI, T., SATOH, H., NOROTA, I. AND ISHIHATA, A.: Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 C1 in canine ventricular myocardium. J. Cardiovasc. Pharmacol. 17: 365-375, 1991.
16. FELDMAN, M. D., COPELAS, L., GWATHMEY, J. K., PHILLIPS, P., WARREN, S. E., SCHOEN, F. J., GROSSMAN, W. AND MORGAN, J. P.: Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331-339, 1987.
17. FELDMAN, M. D., ALDERMAN, J. D., AROESTY, J. M., ROYAL, H. D., FERGUSON, J. J., OWEN, R. M., GROSSMAN, W. AND MCKAY, R. G.: Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J. Clin. Invest. 82: 1661-1669, 1988.
18. FUJIMOTO, S.: Effects of pimobendan, its active metabolite UD-CG 212, and milrinone on isolated blood vessels. Eur. J. Pharmacol. 265: 159-166, 1994.
19. FUJIMOTO, S. AND MATSUDA, T.: Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J. Pharmacol. Exp. Ther. 252: 1304-1311, 1990.
20. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circ. Res. 63: 911-922, 1988.
21. GILBERT, J. C. AND GLANTZ, S. A.: Determinants of left ventricular filling and of the diastolic pressure-volume relations. Circ. Res. 64: 827-852, 1989.
22. HAGEMEIJER, F., BRAND, H. J. AND ROTH, W.: Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J. Cardiovasc. Pharmacol. 14: 302-310, 1989.
23. HONERJAGER, P., SCHAFER-KORTING, M. AND REITER, M.: Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn-Schmiedeberg's Arch. Pharmacol. 318: 112-120, 1981.
24. HONERJAGER, P.: Pharmacology of bipyridine phosphodiesterase III inhibitors. [Review]. Am. Heart J. 121: 1939-1944, 1991.
25. KATZ, S. D., KUBO, S. H., JESSUP, M., BROZENA, S., TROHA, J. M., WAHL, J., COHN, J. N., SONNENBLICK, E. H. AND LEJEMTEL, T. H.: A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am. Heart J. 123: 95-103, 1992.
26. KONSTAM, M. A., COHEN, S. R., WEILAND, D. S., MARTIN, T. T., DAS, D., ISNER, J. M. AND SALEM, D. N.: Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. Am. J. Cardiol. 57: 242-248, 1986.
27. LITTLE, W. C. AND CHENG, C. P.: Effect of exercise on left ventricular-arterial coupling assessed in the pressure-volume plane. Am. J. Physiol. 264: H1629-H1633, 1993.
28. LITTLE, W. C., CHENG, C. P., MUMMA, M., IGARASHI, Y., VINTEN-JOHANSEN, J. AND JOHNSTON, W. E.: Comparison of measures of left ventricular contractile performance from pressure-volume loops in conscious dogs. Circulation 80: 1378-1387, 1989.
29. LITTLE, W. C., CHENG, C. P., PETERSON, T. AND VINTEN-JOHANSEN, J.: Response of the left ventricular end-systolic pressure-volume relation in conscious dogs to a wide range of contractile states. Circulation 78: 736-745, 1988.
30. MARZO, K. P., FREY, M. J., WILSON, J. R., LIANG, B. T., MANNING, D. R., LANOCE, V. AND MOLINOFF, P. B.: Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ. Res. 69: 1546-1556, 1991.
31. MORGAN, J. P., GWATHMEY, J. K., DEFEO, T. T. AND MORGAN, K. G.: The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle. Circulation 73: III65-77, 1986.
32. NOZAWA, T., CHENG, C. P., NODA, T. AND LITTLE, W. C.: The relation between left ventricular oxygen consumption and pressure-volume area in conscious dogs. Circulation 89: 810-817, 1994.
33. PACKER, M.: Neurohormonal interactions and adaptations in congestive heart failure. [Review]. Circulation 77: 721-730, 1988.
34. PERREAULT, C. L., SHANNON, R. P., KOMAMURA, K., VATNER, S. F. AND MORGAN, J. P.: Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J. Clin. Invest. 89: 932-938, 1992.
35. REMME, W. J.: Inodilator therapy for heart failure. Early, late, or not at all? [Review]. Circulation 87: IV97-IV107, 1993.
36. RUEGG, J. C., PFITZER, G., EUBLER, D. AND ZEUGNER, C.: Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)- pyridazinone. Arzneim.-Forsch./Drug Res. 34: 1736-1738, 1984.
37. VAN MEEL, J. C. A.: Effects of some cardiotonic agents on contractility of skinned fibers from mammalian heart. Arzneim.-Forsch./Drug Res. 37: 679-682, 1987.
38. VAN MEEL, J. C. A., ENTZCROTH, M., REDEMANN, N. AND HAIGH, R. M.: Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate. Arzneim.-Forsch./ Drug Res. 45: 136-141, 1995a.
39. VAN MEEL, J. C. A., REDEMANN, N., DIEDEREN, W. AND HAIGH, R. M.: Low concentrations of UD-CG 212 enhance myocyte contractility by an increase in calcium responsiveness in the presence of inorganic phosphate. Naunyn-Schmiedeberg's Arch. Pharmacol. 351: 644-650, 1995b.